AZNETAC

A zebrafish model of pancreatic neuroendocrine tumor to test resistance to antiangiogenic compounds

 Coordinatore THE UNIVERSITY OF MANCHESTER 

 Organization address address: OXFORD ROAD
city: MANCHESTER
postcode: M13 9PL

contact info
Titolo: Ms.
Nome: Liz
Cognome: Fay
Email: send email
Telefono: 441613000000

 Nazionalità Coordinatore United Kingdom [UK]
 Totale costo 221˙606 €
 EC contributo 221˙606 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2012-IEF
 Funding Scheme MC-IEF
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-07-01   -   2015-06-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    THE UNIVERSITY OF MANCHESTER

 Organization address address: OXFORD ROAD
city: MANCHESTER
postcode: M13 9PL

contact info
Titolo: Ms.
Nome: Liz
Cognome: Fay
Email: send email
Telefono: 441613000000

UK (MANCHESTER) coordinator 221˙606.40

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

ones    antiantiogenesis    autochthonous    blood    model    tumours    angiogenesis    transgenic    human    resistance    pancreatic    zebrafish    vessels    sunitinib    data    mechanisms    drugs    compounds    resistant    neuroendocrine    nets   

 Obiettivo del progetto (Objective)

Neuroendocrine tumours (NETs) consist of a range of rare neoplasms that may arise from any (neuro)endocrine cell situated in any part of the human body. Despite the recent approval of two new drugs (sunitinib and everolimus) for pancreatic NETs, innate resistance is frequently encountered in these tumours and patients showing a response invariably relapse due to acquisition of resistance. Moreover, while new data are being generated, including publication of the exome sequence of pancreatic neuroendocrine tumours, the mechanisms of resistance to angiogenesis compounds have not yet been completely elucidated. Data from animal models are scarce about resistance mechanisms to antiantiogenesis compounds in NETs. The zebrafish has recently emerged as an invaluable model system for the study of human cancers. Our main aim is to establish a new zebrafish model for neuroendocrine tumours that can be used to investigate resistance mechanisms to antiantiogenesis compounds. The main hypothesis of our proposal is that we will be able to develop an autochthonous transgenic model of pancreatic neuroendocrine tumours in zebrafish and combine this with the already established kdrl-eGFP transgenic zebrafish line with blood vessels expressing a green fluorescent protein. The objectives of the study are: 1. To engineer an autochthonous transgenic zebrafish model of neuroendocrine pancreatic tumours. 2. Couple the above model with zebrafish possessing GFP-marked blood vessels. 3. Test the activity of known antiantiogenesis compounds such as sunitinib and novel ones in the model generated. 4. To establish lines of fishes resistant to antiantiogenesis drugs. Angiogenesis being a complex and dynamic process, the in vivo study of acquired resistance in tumours and accompanying alterations in tumour vasculature will hopefully give us a better understanding of how sensitive NETs turn into resistant ones.

Altri progetti dello stesso programma (FP7-PEOPLE)

INMARESS (2010)

In vivo magnetic resonance spectroscopy studies of muscle mitochondrial function in mice

Read More  

MECHANISM REJECTION (2011)

Equilibrium Rejection of a Mechanism

Read More  

ICARUS (2010)

International Cooperation for the Advancement of Research on the Underlying System of Human Thermoregulation

Read More